Peptide Receptor Radionuclide Therapy Market Size, Share, and Growth Forecast 2026 - 2033

The global peptide receptor radionuclide therapy market size is expected to be valued at US$ 1,030.4 million in 2026 and projected to reach US$ 2,277.9 million by 2033, growing at a CAGR of 12.0% between 2026 and 2033.

Rising incidence of neuroendocrine tumors worldwide is the primary force behind this rapid expansion. The National Cancer Institute reports steadily increasing neuroendocrine tumor diagnosis rates across recent years, driven partly by improved imaging and awareness.

Growing clinical adoption of Lutetium-177-based radioligand therapies, expanding regulatory approvals, and rising investment in targeted alpha-particle therapies using Actinium-225 continue to widen demand for peptide receptor radionuclide therapy across oncology centers worldwide. Expanding pharmaceutical investment and acquisition activity within this specialized therapy segment further reinforces its strong long-term growth trajectory.

Market Growth Drivers

Rising Global Incidence of Neuroendocrine Tumors

Neuroendocrine tumor incidence continues rising steadily across major global markets. The National Cancer Institute's Surveillance, Epidemiology, and End Results Program reports that neuroendocrine tumor diagnosis rates have increased substantially over the past two decades in the United States. Improved diagnostic imaging techniques, including somatostatin receptor positron emission tomography, are enabling earlier and more accurate tumor detection. This rising diagnosed patient population is directly expanding the addressable market for peptide receptor radionuclide therapy.

The U.S. Food and Drug Administration's approval of Lutathera for gastroenteropancreatic neuroendocrine tumors has further validated this treatment approach among oncologists. As diagnostic capabilities continue improving worldwide, the pool of patients eligible for radioligand therapy is expected to keep expanding across both developed and emerging healthcare markets. Growing referral pathways between primary oncologists and specialized nuclear medicine centers are reinforcing this expanding treatment funnel.

Expanding Clinical Pipeline for Targeted Radioligand Therapies

Pharmaceutical investment in radioligand therapy development is accelerating rapidly worldwide. Companies including Novartis and Eli Lilly and Company have expanded clinical trial programs targeting new tumor indications beyond gastroenteropancreatic neuroendocrine tumors. The National Institutes of Health's clinical trials registry shows a growing number of active trials evaluating Actinium-225 and other alpha-emitting isotopes for prostate and other solid tumors. This expanding pipeline reflects strong confidence in radioligand therapy's targeted mechanism of action, which limits damage to healthy tissue compared with conventional systemic chemotherapy.

Growing pharmaceutical acquisition activity within the radioligand therapy space, including recent large-scale industry transactions, signals expectations of continued strong demand. This expanding clinical pipeline is expected to broaden treatment indications and strengthen long-term market growth prospects significantly, drawing further capital investment from major oncology-focused pharmaceutical companies.

Market Restraints

Limited Radioisotope Production and Supply Chain Constraints

Peptide receptor radionuclide therapy depends on a limited global supply of medical radioisotopes. The International Atomic Energy Agency has noted that Lutetium-177 and Actinium-225 production remains concentrated among a small number of specialized nuclear reactors and cyclotron facilities worldwide. This limited production capacity creates supply chain vulnerabilities that can delay treatment access for patients. Radioisotopes also have short half-lives, requiring precise coordination between production facilities and treatment centers.

Any disruption in reactor operations or transportation logistics can directly affect patient treatment schedules, creating a persistent operational challenge for healthcare providers and therapy manufacturers alike. Expanding production capacity requires significant capital investment and multi-year regulatory approval timelines.

High Treatment Costs and Reimbursement Complexity

Peptide receptor radionuclide therapy involves substantial per-treatment costs due to specialized radioisotope production and handling requirements. The Centers for Medicare and Medicaid Services applies specific coverage and billing codes for radioligand therapy that can vary across different care settings. This complexity can delay reimbursement approval and create financial uncertainty for treatment centers offering these therapies.

Smaller nuclear medicine centers and hospitals in emerging markets often lack the capital required to establish dedicated radioligand therapy infrastructure. This cost barrier limits broader treatment access, particularly across price-sensitive healthcare systems in developing regions worldwide, slowing the pace of global market penetration.

Market Opportunities

Growing Adoption of Actinium-225 Targeted Alpha Therapy

Targeted alpha therapy using Actinium-225 presents a substantial growth opportunity for market participants. Alpha-emitting isotopes deliver highly concentrated radiation doses within a very short tissue range, offering greater tumor-killing potential with reduced damage to surrounding healthy cells compared with beta-emitting isotopes such as Lutetium-177. Companies including RadioMedix Inc. are advancing Actinium-225-based clinical programs targeting neuroendocrine tumors and other solid cancers. The U.S. Food and Drug Administration has granted fast-track designations to several alpha-emitter therapy candidates, signaling regulatory support for accelerated development.

As global radioisotope production capacity for Actinium-225 expands through new supply partnerships, manufacturers investing early in alpha therapy platforms stand to capture significant first-mover advantage. This emerging therapy class offers a compelling opportunity for companies seeking differentiated positioning within the broader radioligand therapy market over the coming years, particularly as clinical evidence supporting alpha-emitter safety and efficacy continues to accumulate.

Expansion of Radioligand Therapy Manufacturing Capacity in Asia-Pacific

Asia-Pacific presents a significant expansion opportunity for radioligand therapy manufacturers and service providers. Rising neuroendocrine tumor diagnosis rates across China and Japan are creating new demand for specialized nuclear medicine infrastructure. Governments across the region are investing in domestic radioisotope production facilities to reduce reliance on imported supply.

Companies such as ITM Isotope Technologies Munich SE have expanded international partnerships to support radioisotope distribution across emerging Asian markets. Growing academic medical center investment in nuclear medicine training programs is also building the specialized workforce needed to administer these therapies safely. Companies that establish early manufacturing and distribution partnerships across this region can secure long-term supply agreements ahead of slower-moving competitors. This expanding regional infrastructure investment supports strong long-term growth potential for radioligand therapy across Asia-Pacific markets, particularly as domestic production capacity continues to scale.

Radioisotope Analysis

Lutetium-177 (Lu-177) held the leading position among radioisotopes, accounting for approximately 92% share of the market in 2026. This overwhelming dominance reflects Lu-177's established clinical track record and regulatory approval status across major markets. The U.S. Food and Drug Administration's approval of Lutathera, a Lu-177-based therapy, for gastroenteropancreatic neuroendocrine tumors has driven widespread clinical adoption since its introduction. Lu-177's favorable beta-particle emission profile and moderate half-life make it well suited for existing nuclear medicine infrastructure and handling protocols.

Companies including Novartis maintain extensive Lu-177 manufacturing and distribution networks supporting global therapy access. While Actinium-225 is growing rapidly due to its alpha-emitting properties, its smaller current production scale keeps Lutetium-177 the overwhelmingly dominant radioisotope category through the near-term forecast period. Continued manufacturing capacity expansion should further reinforce this segment's leading position.

Disease Indication Analysis

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) led the disease indication category, capturing an estimated 58% share of the market in 2026. This leadership reflects GEP-NETs' status as the primary approved indication for peptide receptor radionuclide therapy across major regulatory markets. The National Cancer Institute recognizes gastroenteropancreatic tumors as among the most common neuroendocrine tumor types diagnosed annually.

Clinical trial data supporting Lutathera's approval specifically targeted this patient population, establishing a strong evidence base that continues driving physician confidence. Oncologists increasingly consider radioligand therapy as a standard treatment option following disease progression on somatostatin analog therapy. While Bronchopulmonary Neuroendocrine Tumors are emerging as a faster-growing indication, GEP-NETs' established regulatory pathway and clinical evidence base keep it the leading disease indication category through the forecast period.

North America Peptide Receptor Radionuclide Therapy Market Trends and Insights

North America dominated the peptide receptor radionuclide therapy (PRRT) market, accounting for an estimated 43% share in 2026. The region's leadership is supported by widespread adoption of radioligand therapies, favorable reimbursement, and an extensive network of nuclear medicine centers. According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the United States performs millions of nuclear medicine procedures annually, supported by hundreds of PET/CT facilities and specialized treatment centers.

The increasing incidence of neuroendocrine tumors (NETs), estimated at approximately 7 cases per 100,000 population annually, continues to expand the eligible patient pool. Ongoing investments in radiopharmaceutical manufacturing capacity and growing clinical research activities further strengthen regional demand, positioning North America to maintain its leading market position throughout the forecast period.

U.S. Peptide Receptor Radionuclide Therapy Market Size

The United States accounted for the largest share of the North American PRRT market due to its advanced healthcare infrastructure and early adoption of radioligand therapies. The U.S. Food and Drug Administration (FDA) approval of Lutathera® (Lu-177 DOTATATE) significantly accelerated PRRT adoption nationwide. According to the National Cancer Institute (NCI), neuroendocrine tumors represent one of the fastest-growing cancer types in the country, with prevalence continuing to rise because of improved diagnosis and longer patient survival. The presence of leading academic centers, expanding theranostics programs, and increasing investments in domestic radioisotope production continue supporting robust market growth.

Europe Peptide Receptor Radionuclide Therapy Market Trends and Insights

Europe represented the second-largest regional market for peptide receptor radionuclide therapy in 2026, supported by its well-established nuclear medicine infrastructure and long history of PRRT adoption. Countries including Germany, the Netherlands, France, and Italy have served as pioneers in clinical implementation of radioligand therapy.

According to the European Association of Nuclear Medicine (EANM), Europe operates more than 1,300 PET/CT systems and numerous specialized radionuclide therapy centers, facilitating broad patient access. Regulatory approvals through the European Medicines Agency (EMA) and increasing investment in theranostics research continue supporting market expansion. Growing incidence of gastroenteropancreatic neuroendocrine tumors and expanding clinical trials involving next-generation alpha-emitting therapies are expected to sustain Europe's strong contribution throughout the forecast period.

Germany Peptide Receptor Radionuclide Therapy Market Size

Germany held the largest share of the European PRRT market owing to its advanced nuclear medicine infrastructure and strong domestic radiopharmaceutical manufacturing capabilities. The country hosts ITM Isotope Technologies Munich SE, a leading producer of medical radioisotopes, while numerous university hospitals operate specialized theranostics programs. Germany performs one of the highest volumes of nuclear medicine procedures in Europe, supported by widespread PET/CT availability and experienced clinical specialists.

Continuous investments in radiopharmaceutical research, expanding clinical trials, and increasing adoption of precision oncology continue reinforcing Germany's leadership position and supporting long-term market growth.

U.K. Peptide Receptor Radionuclide Therapy Market Size

The United Kingdom accounted for a significant share of the European PRRT market, supported by the National Health Service (NHS) and expanding access to specialized cancer therapies. The National Institute for Health and Care Excellence (NICE) has recommended PRRT for eligible patients with advanced neuroendocrine tumors, facilitating broader clinical adoption. Increasing investments in molecular imaging, theranostics centers, and academic collaborations have strengthened treatment capacity across major oncology hospitals. Rising neuroendocrine tumor incidence and ongoing participation in international radioligand therapy clinical trials continue supporting steady market expansion throughout the forecast period.

France Peptide Receptor Radionuclide Therapy Market Size

France represented an important European market for peptide receptor radionuclide therapy, supported by a strong public healthcare system and advanced oncology infrastructure. Organizations such as the French Alternative Energies and Atomic Energy Commission (CEA) have played a significant role in nuclear medicine research and radiopharmaceutical innovation.

The country continues expanding access to PET imaging and targeted radionuclide therapies through specialized cancer centers. Growing investments by companies including Curium in domestic radiopharmaceutical manufacturing and increasing participation in clinical research have strengthened the national PRRT ecosystem, supporting steady market growth through the forecast period.

Asia-Pacific Peptide Receptor Radionuclide Therapy Market Trends and Insights

Asia-Pacific is projected to register the fastest growth in the global PRRT market through 2033, driven by expanding healthcare expenditure and increasing nuclear medicine capacity. According to the International Atomic Energy Agency (IAEA), the region has witnessed rapid growth in PET/CT installations and radionuclide therapy facilities, particularly in China, Japan, India, and South Korea. Rising incidence of neuroendocrine tumors, improving access to molecular imaging, and government investments in domestic radioisotope production are accelerating market expansion.

Several countries are also increasing participation in theranostics clinical trials and establishing dedicated centers for precision oncology. These developments are expected to significantly strengthen Asia-Pacific's contribution to the global PRRT market during the forecast period.

India Peptide Receptor Radionuclide Therapy Market Size

India is emerging as a promising PRRT market due to expanding nuclear medicine infrastructure and increasing cancer care investments. According to the Department of Atomic Energy (DAE) and Bhabha Atomic Research Centre (BARC), India continues to strengthen domestic radioisotope production while supporting growing numbers of nuclear medicine departments nationwide. Increasing availability of PET/CT scanners and specialized oncology hospitals has improved access to PRRT for neuroendocrine tumor patients. Rising cancer awareness, expanding health insurance coverage, and ongoing government investments in tertiary healthcare infrastructure are expected to drive sustained market growth.

Japan Peptide Receptor Radionuclide Therapy Market Size

Japan maintained a strong position in the Asia-Pacific PRRT market due to its advanced healthcare system and extensive nuclear medicine infrastructure. The country operates one of the highest numbers of PET scanners per capita globally, supporting widespread molecular imaging and theranostics adoption. Regulatory support for innovative oncology treatments and collaborations between healthcare institutions and radiopharmaceutical companies have strengthened market development.

Increasing prevalence of cancer associated with an aging population, coupled with continued investment in precision medicine and radioisotope supply partnerships, is expected to support steady growth of the Japanese PRRT market.

Southeast Asia Peptide Receptor Radionuclide Therapy Market Size

Southeast Asia is gradually emerging as a growing market for peptide receptor radionuclide therapy as countries expand access to advanced oncology care. Nations including Singapore, Thailand, and Malaysia have increased investments in PET/CT imaging, nuclear medicine departments, and specialized cancer hospitals. Support from the International Atomic Energy Agency (IAEA) has strengthened regional capabilities through training, technology transfer, and infrastructure development.

Improving healthcare expenditure, rising cancer incidence, and greater awareness of targeted radionuclide therapies among oncologists are expected to accelerate PRRT adoption, supporting steady market growth across the region over the forecast period.

The peptide receptor radionuclide therapy market remains highly concentrated among a small group of specialized manufacturers. Companies such as Novartis and Eli Lilly and Company compete through established radioisotope supply chains and expanding clinical trial pipelines.

Smaller specialized firms including RadioMedix Inc. and Orano Med differentiate through novel alpha-emitter therapy platforms. Market leaders are pursuing acquisition-led growth strategies to secure radioisotope production capacity and expand treatment indications. Strategic partnerships between pharmaceutical companies and nuclear reactor operators are becoming increasingly common to secure long-term isotope supply. This vertical integration trend reflects the critical importance of supply chain control within this specialized and rapidly growing therapy market.

Key Developments

• July 2026: Novartis announced that it discontinued development of a Phase 2 radioligand therapy candidate after evaluating clinical data and its strategic research priorities. The decision was made as part of the company's ongoing portfolio optimization efforts, allowing it to focus resources on programs with stronger clinical potential and greater commercial opportunity.
• June 2026: Curium Group, PeptiDream, and PDRadiopharma announced the successful completion of patient dosing in a clinical trial evaluating 64Cu-PSMA-I&T for the imaging of prostate cancer in Japan. The milestone marked the completion of patient enrollment and dosing, advancing the study toward data analysis and evaluation of the investigational radiopharmaceutical's safety and diagnostic performance.
• June 2026: Curium announced a strategic investment of more than €32 million in its facility in Saclay, France, to expand its radiopharmaceutical manufacturing and research capabilities. The investment was intended to strengthen the company's production capacity for diagnostic and therapeutic radiopharmaceuticals while supporting the growing global demand for nuclear medicine products.